Abstract
SLC17A1 protein (NPT1) was the first identified member of the SLC17 phosphate transporter family, and is known to mediate Na+/inorganic phosphate (Pi) co-transport when expressed in Xenopus oocytes. Although this protein was suggested to be a renal polyspecific anion exporter, its transport properties were not well characterized. The clean biochemical approach revealed that proteoliposomes comprising purified NPT1 as the only protein source transport various organic anions such as urate, p-aminohippuric acid (PAH), and acetylsalicylic acid (aspirin) in a membrane potential (Δψ)-driven and Cl- -dependent manner. Human NPT1 carrying an SNP mutation, Thr269Ile, known to increase the risk of gout, exhibited 32% lower urate transport activity compared to the wild type protein, leading to the conclusion that NPT1 is the long searched for transporter responsible for renal urate excretion. In the present article, we summarized the history of identification of the urate exporter and its possible involvement in the dynamism of urate under physiological and pathological conditions.
Keywords: Drug excretion, gout, membrane potential, Na+/inorganic phosphate transporter, non-steroidal anti-inflammatory drug, urate.
Current Molecular Pharmacology
Title:Type 1 Sodium-Dependent Phosphate Transporter acts as a Membrane Potential-Driven Urate Exporter
Volume: 6
Author(s): Takaaki Miyaji, Tatsuya Kawasaki, Natsuko Togawa, Hiroshi Omote and Yoshinori Moriyama
Affiliation:
Keywords: Drug excretion, gout, membrane potential, Na+/inorganic phosphate transporter, non-steroidal anti-inflammatory drug, urate.
Abstract: SLC17A1 protein (NPT1) was the first identified member of the SLC17 phosphate transporter family, and is known to mediate Na+/inorganic phosphate (Pi) co-transport when expressed in Xenopus oocytes. Although this protein was suggested to be a renal polyspecific anion exporter, its transport properties were not well characterized. The clean biochemical approach revealed that proteoliposomes comprising purified NPT1 as the only protein source transport various organic anions such as urate, p-aminohippuric acid (PAH), and acetylsalicylic acid (aspirin) in a membrane potential (Δψ)-driven and Cl- -dependent manner. Human NPT1 carrying an SNP mutation, Thr269Ile, known to increase the risk of gout, exhibited 32% lower urate transport activity compared to the wild type protein, leading to the conclusion that NPT1 is the long searched for transporter responsible for renal urate excretion. In the present article, we summarized the history of identification of the urate exporter and its possible involvement in the dynamism of urate under physiological and pathological conditions.
Export Options
About this article
Cite this article as:
Miyaji Takaaki, Kawasaki Tatsuya, Togawa Natsuko, Omote Hiroshi and Moriyama Yoshinori, Type 1 Sodium-Dependent Phosphate Transporter acts as a Membrane Potential-Driven Urate Exporter, Current Molecular Pharmacology 2013; 6 (2) . https://dx.doi.org/10.2174/18744672113069990035
DOI https://dx.doi.org/10.2174/18744672113069990035 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mouse Models of Human Hearing Disorders
Current Genomics Similar Mechanisms Regulated by γ-Secretase are Involved in Both Directions of the Bi-Directional Notch-Delta Signaling Pathway as well as Play a Potential Role in Signaling Events Involving Type 1 Transmembrane Proteins
Current Stem Cell Research & Therapy Recent Progress Toward Hydrogen Medicine: Potential of Molecular Hydrogen for Preventive and Therapeutic Applications
Current Pharmaceutical Design Management of Hyperglycemia in Gestational Diabetes Mellitus
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Protective Effect of Vitamin B Therapy on Bone and Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Neurological Disorders in Pregnancy
Current Women`s Health Reviews Prevalence of Congenital Heart Disease among Children in Khorramabad (West of Iran)
Cardiovascular & Hematological Disorders-Drug Targets Cardiac Autonomic Nervous System in Heart Failure: Imaging Technique and Clinical Implications
Current Cardiology Reviews Experimental Antiarrhythmic Targets: CaMKII Inhibition – Ready for Clinical Evaluation?
Current Medicinal Chemistry Supraventricular Tachycardia in Fetus: How Can We Treat ?
Current Pharmaceutical Design Protein Cysteine Modifications: (1) Medicinal Chemistry for Proteomics
Current Medicinal Chemistry Nanotechnological Strategies for the Treatment of Neglected Diseases
Current Pharmaceutical Design The Detrimental Effect of Smoking on Female Fertility and IVF Success
Current Women`s Health Reviews Mending a Broken Heart: Bioengineered Patches and Scaffolds for Cardiac Repair
Recent Patents on Biomedical Engineering (Discontinued) Effects of Iron Polymaltose Complex, Ferrous Fumarate and Ferrous Sulfate Treatments in Anemic Pregnant Rats, Their Fetuses and Placentas
Inflammation & Allergy - Drug Targets (Discontinued) Novel Non-rodent Models of Kidney Disease
Current Molecular Medicine Cell-based Treatment of Cerebral Palsy: Still a Long Way Ahead
Current Stem Cell Research & Therapy Selective Serotonin Reuptake Inhibitors in Pregnancy
Current Medicinal Chemistry Cyanosis Due to Methemoglobinemia Induced by Topical Anesthesia in a Premature Infant
Current Drug Therapy A Decade of Targets and Patented Drugs for Chemotherapy of Chagas Disease
Recent Patents on Anti-Infective Drug Discovery